Full-Time

Senior Scientist, Material Science and Technology

Posted on 10/31/2025

CG Oncology

CG Oncology

51-200 employees

Develops bladder cancer oncolytic immunotherapies

Compensation Overview

$136k - $160k/yr

+ Annual Bonus + Equity

Remote in USA

Remote

Category
Biology & Biotech (2)
,
Requirements
  • Master in Biochemistry, Biotechnology, Chemical Engineering, or a related field, or a BSc degree with extensive relevant experience
  • Minimum of 5 years of experience in bioprocess development, preferably in the Gene Therapy industry
  • Hands-on experience with cell culture, virus production, chromatography, and other bioprocessing techniques
  • Expertise in viral vector production or general complex biotechnology processes
  • In-depth understanding of bioprocessing principles and practices
  • Familiarity with regulatory requirements and quality standards for biopharmaceutical manufacturing
  • Strong technical writing skills
Responsibilities
  • Provide technical support for bioprocess development, including cell culture, virus production, purification, and formulation
  • Review executed cGMP documents, extract data from provided documentation to allow data trending
  • Oversee process activities during cGMP manufacturing at CDMO
  • Strong technical writing abilities to support report writing and generation of regulatory filing
  • Collaborate with CDMOs on activities related to cGMP manufacturing, process development and optimization, troubleshooting and process scale-up
  • Work with process development, manufacturing, quality assurance, and regulatory teams to ensure seamless process transfer and integration
  • Prepare and present technical reports, summaries, and presentations to internal and external stakeholders
  • Ensure processes comply with regulatory requirements, including Good Manufacturing Practices
  • Support documentation for regulatory submissions and audits
  • Stay current with industry trends and technological advancements to drive innovation in process development
  • Review and prepare implementation plans for continuous improvement initiatives to enhance process efficiency, yield, and product quality
  • Assists in developing timelines and allocation of resources in support of the Project Management group
  • Coordinate with project teams to ensure project milestones are met
  • Report progress, challenges, and key performance indicators to the Senior Director of MSAT
  • Ensure alignment of process development activities with broader technical operations and company goals

CG Oncology develops immunotherapy treatments for bladder cancer, with a focus on preserving the bladder in patients with urologic cancers. Its lead product, cretostimogene grenadenorepvec, is delivered directly into the bladder to stimulate the immune system to attack non-muscle invasive bladder cancer that does not respond to BCG. The company concentrates on localized bladder cancer immunotherapy, differentiating itself by intravesical delivery and a focus on NMIBC, rather than broad systemic cancer drugs. Its goal is to improve quality of life for patients with NMIBC and other urologic cancers and move toward commercialization.

Company Size

51-200

Company Stage

IPO

Headquarters

Irvine, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • $903M cash funds operations into H1 2029 without dilution.
  • PIVOT-006 topline data expected H1 2026 accelerates approval path.
  • H.C. Wainwright targets $80/share citing strong safety data.

What critics are saying

  • FDA rejected cretostimogene BLA due to BOND-003 durability issues.
  • Merck's pembrolizumab captures 60% BCG-unresponsive NMIBC market.
  • $250M annual burn depletes cash by mid-2028 post-2026 readouts.

What makes CG Oncology unique

  • Cretostimogene grenadenorepvec delivers oncolytic immunotherapy intravesically for BCG-unresponsive NMIBC.
  • CG0070 targets Rb-defective bladder cancer cells via selective adenovirus replication.
  • First randomized Phase 3 trial in intermediate-risk NMIBC with PIVOT-006.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Unlimited Paid Time Off

401(k) Company Match

401(k) Retirement Plan

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Performance Bonus

Health Savings Account/Flexible Spending Account

Company News

Yahoo Finance
Mar 15th, 2026
CG Oncology shares up 131% in a year as DCF model suggests 79% upside potential

CG Oncology has surged 131% over the past year, with shares climbing 54% year-to-date and 20% in the last month to reach $64.29. The cancer-focused biotech has attracted investor attention amid progress in its pipeline. A discounted cash flow analysis suggests the stock may still be undervalued. The model projects free cash flow will shift from losses of $225 million in 2026 and $200 million in 2027 to positive $21 million in 2028, $340 million in 2029 and $590 million in 2030, based on analyst estimates through 2030. The DCF model estimates an intrinsic value of $304 per share, implying the current price is 79% undervalued according to this cash flow-based approach. CG Oncology scores three out of six on valuation checks.

Yahoo Finance
Mar 6th, 2026
H.C. Wainwright raises CG Oncology price target to $80, eyes Phase 3 PIVOT-006 trial as key 2026 catalyst

H.C. Wainwright has raised its price target on CG Oncology to $80 from $75, maintaining a Buy rating. The analyst cited the company's progress toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong safety and durability data. CG Oncology reported FY25 revenue of $4.04 million, exceeding the $515,180 consensus estimate. The company expects topline data from its Phase 3 PIVOT-006 trial in intermediate-risk NMIBC in the coming months, which H.C. Wainwright identified as a key 2026 catalyst. CEO Arthur Kuan described PIVOT-006 as the first randomised registrational trial evaluating an investigational therapy in intermediate-risk NMIBC. Results from the CORE-008 study evaluating cretostimogene combined with gemcitabine are expected next quarter.

Yahoo Finance
Feb 27th, 2026
CG Oncology expects PIVOT-006 Phase 3 data in H1 2026 with $903M cash to fund ops into 2029

CG Oncology reported its 2025 financial results, highlighting approximately $903 million in cash, cash equivalents and marketable securities, sufficient to fund operations into the first half of 2029. The company expects topline data from its PIVOT-006 Phase 3 trial evaluating cretostimogene as adjuvant therapy in intermediate-risk non-muscle invasive bladder cancer in the first half of 2026, nearly a year ahead of schedule. PIVOT-006 is the first randomised Phase 3 trial in this patient population. First results from CORE-008 Cohort CX, evaluating cretostimogene combined with gemcitabine in high-risk non-muscle invasive bladder cancer, are also expected in the first half of 2026. The company strengthened its board in November 2025 with the addition of Christina Rossi, former chief operating officer of Blueprint Medicines.

Business News Today
Apr 28th, 2025
CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025

CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025.

DealForma
Mar 19th, 2025
CG Oncology Raises $437M in IPO

In 2024, biopharma therapeutics and platforms saw significant IPO activity, raising $6.8 billion across 26 IPOs. Notable IPOs include CG Oncology's $437M in January, Kyverna Therapeutics' $367M in February, Bicara Therapeutics' $362M in August, Septerna's $331M in October, and Upstream Bio's $293M in September. Overall, the sector experienced increased deal activity and higher capital raised compared to 2023, indicating a stronger financing environment.

INACTIVE